Harlan reports on a new study testing the effectiveness of the OCD drug fluvoxamine in treating COVID; Howie reflects on the potential of continuous glucose monitoring for people with diabetes. And they’re joined by Dr. Utibe Essien of the University of Pittsburgh to discuss the barriers preventing people of color from getting innovative new treatments and medications.

Links:

“Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial”

Utibe Essien: “Association of Neighborhood Disadvantage and Anticoagulation for Patients with Atrial Fibrillation in the Veterans Health Administration: the REACH-AF Study”

“Prevalence and Correlates of Patient Rationing of Insulin in the United States: A National Survey”

Harlan Krumholz: “Life Expectancy after Myocardial Infarction by Hospital Performance”

“Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites”

Antiracism in Medicine podcast

“Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes”

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.

Julie Norem, The Positive Power of Negative Thinking